A review of the industry for Journal of Commercial Biotechnology
Several startups are now pursuing the potential of enzymatic synthesis as a faster and more efficient route for synthesizing longer DNA sequences than is possible with traditional chemical means.
A partnership between two California firms, Codexis CDXS and Molecular Assemblies, is focused on a radical new way of writing DNA.
With a new way to write DNA, Mike Kamdar and his team at Molecular Assemblies are poised to disrupt just about any industry you can imagine.
The field of synthetic biology has made huge leaps forward in the last decade. In an editorial article for Science, our CSO Dr. Bill Efcavitch and synthetic biology leaders lay out remaining technological challenges in the field to advance genome design, DNA synthesis, genome editing, and chromosome construction.